These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37464962)

  • 21. The MINT Sprint: Exploring a Fast Administration Procedure with an Expanded Multilingual Naming Test.
    Garcia DL; Gollan TH
    J Int Neuropsychol Soc; 2022 Sep; 28(8):845-861. PubMed ID: 34463235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which language is more affected in bilinguals with Alzheimer's disease? Diagnostic sensitivity of the Multilingual Naming Test.
    Gollan TH; Stasenko A; Salmon DP
    Neuropsychology; 2023 Jul; 37(5):595-606. PubMed ID: 36931816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease.
    Yassine HN; Feng Q; Chiang J; Petrosspour LM; Fonteh AN; Chui HC; Harrington MG
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort.
    Alegret M; Sotolongo-Grau O; de Antonio EE; Pérez-Cordón A; Orellana A; Espinosa A; Gil S; Jiménez D; Ortega G; Sanabria A; Roberto N; Hernández I; Rosende-Roca M; Tartari JP; Alarcon-Martin E; de Rojas I; Montrreal L; Morató X; Cano A; Rentz DM; Tárraga L; Ruiz A; Valero S; Marquié M; Boada M
    Alzheimers Res Ther; 2022 Mar; 14(1):43. PubMed ID: 35303916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis.
    Willette AA; Calhoun VD; Egan JM; Kapogiannis D;
    Psychiatry Res; 2014 Nov; 224(2):81-8. PubMed ID: 25194437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
    Wang L;
    Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value for cerebrospinal fluid Alzheimer's disease profile of different measures of verbal episodic memory in patients with MCI.
    Salvadori N; Torrigiani EG; Paoletti FP; Chipi E; Montanucci C; Verderosa C; Siena E; Fruttini D; Parnetti L
    Sci Rep; 2024 May; 14(1):12235. PubMed ID: 38806521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.
    Bondi MW; Edmonds EC; Jak AJ; Clark LR; Delano-Wood L; McDonald CR; Nation DA; Libon DJ; Au R; Galasko D; Salmon DP
    J Alzheimers Dis; 2014; 42(1):275-89. PubMed ID: 24844687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
    Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
    J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple category verbal fluency in mild cognitive impairment and correlation with CSF biomarkers for Alzheimer's disease.
    Mirandez RM; Aprahamian I; Talib LL; Forlenza OV; Radanovic M
    Int Psychogeriatr; 2017 Jun; 29(6):949-958. PubMed ID: 28179036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.